Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Niraparib Combined With Bevacizumab as Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-line Platinum-based Chemotherapy With Bevacizumab

Trial ID # NCT03326193; OVARIO
Phase II
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Niraparib
Alternate Drug Names MK4827, Zejula
Drugs in Trial Bevacizumab, Carboplatin, Niraparib, Paclitaxel
Eligible Participant

Newly diagnosed high grade serous or endometrioid stage IIIb/IV ovarian cancer with CR or PR after first-line therapy

Patients Enrolled

105; 79% stage III, 63% w/ neoadjuvant chemotherapy

Therapy Setting

Maintenance

Study Design

Open-Label, Non-randomized

Efficacy

PFS (6 months): 89.5%

Conclusion

Niraparib + bevacizumab maintenance treatment does not appear to cause cumulative toxicities and shows promising PFS

Reference

Hardesty MM et al. Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab. SGO (2020) abstract 4
https://sgo.confex.com/sgo/2020/meetingapp.cgi/Paper/15907